General
Preferred name
LIOTHYRONINE
Synonyms
LIOTHYRONINE (L- isomer) SODIUM ()
Thyroid hormone ()
LIOTHYRONINE SODIUM ()
Sodium L-3,3',5-triiodothyronine ()
3,3',5-Triiodo-L-thyronine sodium ()
T3 Sodium salt ()
Triostat ()
Cytomel ()
L-3,3',5-Triiodothyronine ()
Tresitope ()
3,3',5-Triiodo-L-thyronine ()
triiodothyronine ()
Lyothyronine ()
O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine ()
T3 ()
Triiodothyronine (sodium) ()
3,3',5-Triiodo-L-thyronine (sodium) ()
T3 (sodium) ()
Liothyrionine ()
Liothyronine (sodium) ()
T3, Liothyronine, 3,3',5-Triiodo-L-thyronine ()
Liothyronine I-131 ()
L-triiodothyronine sodium salt ()
Liothyronine sodium salt ()
Rathyronine sodium, (s)- ()
Liotrix (t3) ()
Lyothyronin ()
Triiodothyronine Sodium, Levo ()
Cytobin ()
Rathyronine hydrochloride, (s)- ()
Thybon ()
Cynomel ()
Triiodothyronine ()
NSC-758175 ()
Liothyronine hydrochloride ()
Triiodothyronine sodium salt ()
NSC-80774 ()
L-triiodothyronine hydrochloride ()
Tertroxin ()
Triiodothyronine,evans ()
T3 (liotrix) ()
Ibiothyron ()
Basoprocin ()
Thyrolar-1 ()
Thyrolar-5 ()
Euthroid-0.5 ()
LEVOTHYROXINE SODIUM RELATED COMPOUND LIOTHYRONINE ()
Euthroid-3 ()
NSC-80203 ()
Thyrolar-2 ()
Thyrolar-3 ()
Liotironina ()
Euthroid-2 ()
RATHYRONINE ()
CYRONINE ()
Thyrolar-0.25 ()
Thyrolar-0.5 ()
RATHYRONINE, (S)- ()
Euthroid-1 ()
3,5,3'-TRIIODOTHYRONINE, L- ()
Triiodothyronine (T3 Or Liothyronine, Active) (6-11%) ()
LIOTHYRONINE I 131 ()
Liothyronine i-125 ()
Liothyronine (125i) ()
LIOTHYRONINE I 125 ()
L-3,3',5-Triiodothyronine (sodium salt hydrate) ()
3,3?,5-Triiodo-L-thyronine ()
LIOTIRONINA ()
P&D ID
PD010128
CAS
55-06-1
6893-02-3
57164-27-9
20196-64-9
15785-49-6
24359-14-6
345957-19-9
Tags
available
drug candidate
drug
Approved by
FDA
First approval
1956
Drug indication
Thyroid Hormone
Radioactive Agent,Thyroid Hormone
Hypothyroidism
Congestive heart failure
Radioactive Agent
Drug Status
approved
vet_approved
investigational
Max Phase
4.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
HALF-LIFE
The half-life of liothyronine is reported to be between 1 and 2 days.[T460]
PHARMACODYNAMICS
In hormonal replacement, liothyronine is more potent and present a faster action when compared to levothyroxine but the time of action is significantly shorter. The type of treatment needs to be well evaluated as the fast correction of thyroid hormones in certain diseases presents additional risks such as heart failure.[T457] The onset of activity is observed a few hours after administration and the maximum effect is observed after 2-3 days.[FDA label] Treatment with liothyronine has been shown to produce normal plasma levels of T3 hormone but to have no effect on the T4 plasma concentration.[T463]
MOA
Liothyronine replaces endogenous thyroid hormone and then exerts its physiologic effects by controlling DNA transcription and protein synthesis. This effect on DNA is obtained by the binding of liothyronine to the thyroid receptors attached to DNA. Exogenous liothyronine exerts all the normal effects of the endogenous thyroid T3 hormone. Hence, it increases energy expenditure, accelerates the rate of cellular oxidation stimulating growth, maturation, and metabolism of the body tissues, aids in myelination of nerves and development of synaptic processes in the nervous system and enhances carbohydrate and protein metabolism.[T276]
ROE
The main elimination of thyroid hormones is known to be done via the kidneys from which less than 2.5% of the excreted drug is represented by the unchanged drug. This elimination route is reduced with age. A portion of the metabolic products of liothyronine is excreted to the bile and gut where they can be part of enterohepatic recirculation.[L5587]
INDICATION
Liothyronine is officially approved for the following indications: - Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. - As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer. - As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label] In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457] The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457] Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label]
TOXICITY
The reported oral LD50 of liothyronine in the rat is higher than 4540 mg/kg. When overdosage is registered, symptoms of hyperthyroidism are reported as well as confusion, disorientation, cerebral embolism, seizure, shock, coma, and death. The symptoms of overdose can be presented immediately or several days after overdose ingestion. In an overdose state, reduce the dose of liothyronine and do supportive treatment.[FDA label] There are no reports studying the carcinogenic, and mutagenic potential nor on the effects of liothyronine on fertility.[FDA label]
ABSORPTION
Thyroid hormones are well absorbed orally. From these hormones, liothyronine is almost completely absorbed and it does not present changes in the absorption rate due to concomitant administration of food.[T322]liothyronin Multiple administration of 50 mcg of liothyronine provided a maximal plasma concentration of total T3 of 346 ng/dL in about 2.5 hours with an AUC of 4740 ng.h/dL.[A175435]
PHARMACODYNAMICS
In hormonal replacement, liothyronine is more potent and present a faster action when compared to levothyroxine but the time of action is significantly shorter. The type of treatment needs to be well evaluated as the fast correction of thyroid hormones in certain diseases presents additional risks such as heart failure.[T457] The onset of activity is observed a few hours after administration and the maximum effect is observed after 2-3 days.[FDA label]; ; Treatment with liothyronine has been shown to produce normal plasma levels of T3 hormone but to have no effect on the T4 plasma concentration.[T463]
TOXICITY
The reported oral LD50 of liothyronine in the rat is higher than 4540 mg/kg. When overdosage is registered, symptoms of hyperthyroidism are reported as well as confusion, disorientation, cerebral embolism, seizure, shock, coma, and death. The symptoms of overdose can be presented immediately or several days after overdose ingestion. In an overdose state, reduce the dose of liothyronine and do supportive treatment.[FDA label]; ; There are no reports studying the carcinogenic, and mutagenic potential nor on the effects of liothyronine on fertility.[FDA label]
DESCRIPTION
Thyroid hormone receptor agonist
(GtoPdb)
METABOLISM
Liothyronine is mainly metabolized in the liver where it is deiodinated to diiodothyronine and monoiodothyronine followed by conjugation with glucuronides and sulfates.[L5587] One of the formed metabolites formed by the conjugation and decarboxylation is tiratricol. The iodine released by the metabolism of liothyronine is later taken and used within the thyroid cells.[T122]
INDICATION
Liothyronine is officially approved for the following indications:; ; - Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.; ; - As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer.; ; - As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label]; ; In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457]; ; The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457]; ; Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label]
DESCRIPTION
FXR antagonist; selectively active in intestines; orally bioavailable
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
33
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
IPPI - DB
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NURSA ligand set
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
114
Molecular Weight
650.79
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
3.95
TPSA
92.78
Fraction CSP3
0.13
Chiral centers
1.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Thyroid hormone receptor agonist
Thyroid hormone receptor alpha agonist
Hormone replacement agent
thyroid hormone stimulant
Target
Thyroid hormone receptor
TR??
THRA, THRB
Endogenous Metabolite
THR
Pathway
Endocrinology/Hormones
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Primary Target
Other Nuclear Receptors
Member status
member
Indication
hypothyroidism, myxedema coma
Therapeutic Class
Hormone Replacement Agents
Recommended Cell Concentration
None
Source data
